ECRM recruits new vice president for health and beauty
CLEVELAND A former executive from the joint venture between Johnson & Johnson and Merck will soon become vice president of ECRM’s health and beauty care category, ECRM announced Thursday.
Paul Nunnari’s 25 years of previous experience include terms as vice president of sales at Johnson & Johnson Merck-Joint Venture, vice president of sales for McNeil Consumer Healthcare and vice president of trade development for the Johnson & Johnson Consumer Group. He also served as vice president of sales for the start-up company Ultreo, as well as serving on advisory boards of organizations such as the National Association of Chain Drug Stores.
ECRM said that it looked forward to his positive effect on its health and beauty care category.
FDA posts information regarding regulation of supplements
ROCKVILLE, Md. Countering the misconstrued notion that dietary supplements are unregulated in the United States, the Food and Drug Administration on Monday posted to its site a detailed explanation not only as to how supplements are regulated, but how those regulations are enforced.
“Federal law requires that every dietary supplement be labeled as such, either with the term ‘dietary supplement’ or with a term that substitutes a description of the product’s dietary ingredient for the word ‘dietary’ (e.g., ‘herbal supplement’ or ‘calcium supplement’),” the FDA stated.
And while no supplement manufacturer is required to submit safety or efficacy data in support of its product before going to market, those products are still regulated. Any supplement advertisement claims, for example, are vetted by the Federal Trade Commission, and the FDA pays close attention to any safety flags. “Once a dietary supplement is on the market, FDA has certain safety monitoring responsibilities. These include monitoring mandatory reporting of serious adverse events by dietary supplement firms and voluntary adverse event reporting by consumers and health care professionals. As its resources permit, FDA also reviews product labels and other product information, such as package inserts, accompanying literature, and Internet promotion,” the agency stated.
NAD upholds claims for non-drowsy Claritin
NEW YORK As part of a challenge brought forth by McNeil Consumer Healthcare, the National Advertising Division of the Council of Better Business Bureaus on Tuesday determined that certain claims made by Schering-Plough HealthCare Products in a commercial that compares use of Claritin as a non-sedating allergy relief alternative to Zyrtrec, which can cause drowsiness, were adequately supported by the evidence.
However, NAD did recommend that Schering-Plough modify or discontinue the claim that “Most pharmacists caution that Zyrtec causes drowsiness,” because that claim was unsubstantiated.
Schering-Plough, in its advertiser’s statement, said it accepts the NAD’s decision and “will take it into consideration in future advertising relating to this issue.”